The current serum tumour markers α-fetoprotein, human chorionic gonadotrophin, and lactate dehydrogenase show limited value for testicular cancer relapse detection. A recent study highlights that false-positive elevations in follow-up monitoring are common and, conversely, many patients do not have elevations despite proven relapse. These findings highlight the potential for circulating microRNAs to be used as improved biomarkers for relapse detection.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Kollmannsberger, C. et al. Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance. J. Clin. Oncol. 33, 51–57 (2015).
Javadpour, N. & Soares, T. False-positive and false-negative alpha-feto protein and human chorionic gonadotropin assays in testicular cancer: a double blind study. Cancer 48, 2279–2281 (1981).
Germà, J. R., Llanos, M., Tabernero, J. M. & Mora, J. False elevations of alpha-fetoprotein associated with liver dysfunction in germ cell tumors. Cancer 72, 2491–2494 (1993).
Germa, J. R., Arcusa, A. & Casamitjana, R. False elevations of human chorionic gonadotropin associated to iatrogenic hypogonadism in gonadal germ cell tumors. Cancer 60, 2489–2493 (1987).
Fischer, S. et al. The value of tumour markers in the detection of relapse—lessons learned from the Swiss Austrian German Testicular Cancer Cohort study. Eur. Urol. Open Sci. 50, 57–60 (2023).
Murray, M. J., Huddart, R. A. & Coleman, N. The present and future of serum diagnostic tests for testicular germ cell tumours. Nat. Rev. Urol. 13, 715–725 (2016).
Leão, R. et al. Circulating microRNAs, the next-generation serum biomarkers in testicular germ cell tumours: a systematic review. Eur. Urol. 80, 456–466 (2021).
Fankhauser, C. D. et al. Detection of recurrences using serum miR-371a-3p during active surveillance in men with stage I testicular germ cell tumours. Br. J. Cancer 126, 1140–1144 (2022).
Lafin, J. et al. Refining the serum miR-371a-3p test for viable germ cell tumor detection: identification and definition of an indeterminate range. Preprint at Research Square https://doi.org/10.21203/rs.3.rs-2644890/v1 (2023).
Fern, L. A. et al. Pre-implementation assessment of the acceptability of using circulating microRNAs for follow-up of malignant germ-cell tumors. Clin. Genitourin. Cancer 19, 381–387 (2021).
Acknowledgements
The authors acknowledge grant funding from the National Cancer Institute of the National Institutes of Health (reference PAR-18-317; UH3CA240688), the St. Baldrick’s Foundation (reference 358099) and the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). They are grateful for support from the Max Williamson Fund and from Christiane and Alan Hodson, in memory of their daughter Olivia.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Murray, M.J., Scarpini, C.G. & Coleman, N. Serum tumour markers for testicular cancer recurrence. Nat Rev Urol 20, 459–460 (2023). https://doi.org/10.1038/s41585-023-00782-7
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41585-023-00782-7
